H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
15%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
AmJCaseRep

Annals
ISI-Home

eISSN: 1643-3750

Get your full text copy in PDF

Accelerated versus classical hepatitis B virus vaccination programs in healthcare workers accelerated vs. classical HBV vaccination

Mustafa Oktay Tarhan, All Ihsan Aker, Oguz Resat Sipahi, Gokhan Kardes, Kadir Biberoglu

Med Sci Monit 2006; 12(11): CR467-470

ID: 462699


Background: The aim of this study was to compare the effi cacy of a standard hepatitis B virus vaccination program(day 0–30–60) with an accelerated vaccination program (day 0–10–21) in healthy healthcare workers.
Material/Methods: Participants were randomly assigned to a classical (group 1, days 0, 30, and 60) or an accelerated vaccination program (group 2, days 0, 10, and 21). The vaccine used was 20 μg recombinant hepatitis B vaccine (recombinant hepatitis B vaccine derived from yeast cells, Engerix B, Smith Cline
Beachum). HBV markers were re-examined for the emergence of anti-HBsAg and also to detect
the development of a possible acute HBV infection one, two, and three months after the last dose
of vaccine. Anti-HBsAg titers >10 mIU/l were accepted as protective.
Results: The seroprotection rates were similar one, two, and three months after the last dose of vaccine in both groups. Anti-HBsAg titers in group 1 were higher than in group 2 two and three months after
the last dose of vaccination (p

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree